Impact of Porcine Orexin a on Glucagon Plasma Concentrations in Pigs

Papakonstantinou, P.; Tziris, N.; Κεσίσογλου, Ισαάκ; Gotzamani-Psarrakou, Anna; Tsonidis, Christos; Patsikas, M. N.; Papazoglou, Lyssimachos

doi:10.1177/039463200802100306

Cited by 3 publications

(2 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Together, these data suggest that the tonic action of orexins on arcuate NPY neurons might lead to increased glucagon secretion and reduced liver glycogen. In agreement with such an idea, previous studies have shown that icv injection of either NPY or orexin-A increases circulating glucagon levels (40,41). However, additional experiments are needed to fully prove this hypothesis.…”

Section: Discussionsupporting

confidence: 57%

Orexin activation precedes increased NPY expression, hyperphagia, and metabolic changes in response to sleep deprivation

Martins¹,

Marques²,

Tufik³

et al. 2010

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

Martins PJ, Marques MS, Tufik S, D'Almeida V. Orexin activation precedes increased NPY expression, hyperphagia, and metabolic changes in response to sleep deprivation. Am J Physiol Endocrinol Metab 298: E726 -E734, 2010. First published January 5, 2010 doi:10.1152/ajpendo.00660.2009.-Several pieces of evidence support that sleep duration plays a role in body weight control. Nevertheless, it has been assumed that, after the identification of orexins (hypocretins), the molecular basis of the interaction between sleep and energy homeostasis has been provided. However, no study has verified the relationship between neuropeptide Y (NPY) and orexin changes during hyperphagia induced by sleep deprivation. In the current study we aimed to establish the time course of changes in metabolite, endocrine, and hypothalamic neuropeptide expression of Wistar rats sleep deprived by the platform method for a distinct period (from 24 to 96 h) or sleep restricted for 21 days (SR-21d). Despite changes in the stress hormones, we found no changes in food intake and body weight in the SR-21d group. However, sleep-deprived rats had a 25-35% increase in their food intake from 72 h accompanied by slight weight loss. Such changes were associated with increased hypothalamus mRNA levels of prepro-orexin (PPO) at 24 h followed by NPY at 48 h of sleep deprivation. Conversely, sleep recovery reduced the expression of both PPO and NPY, which rapidly brought the animals to a hypophagic condition. Our data also support that sleep deprivation rapidly increases energy expenditure and therefore leads to a negative energy balance and a reduction in liver glycogen and serum triacylglycerol levels despite the hyperphagia. Interestingly, such changes were associated with increased serum levels of glucagon, corticosterone, and norepinephrine, but no effects on leptin, insulin, or ghrelin were observed. In conclusion, orexin activation accounts for the myriad changes induced by sleep deprivation, especially the hyperphagia induced under stress and a negative energy balance. neuropeptide Y; leptin; glucagon; insulin; liver glycogen; triacylglycerol SEVERAL PIECES OF EVIDENCE support that sleep duration plays a role in body weight control (4, 15, 56). Everson et al. (10), Kushida et al. (24), and Rechtschaffen et al. (46), using an animal model, characterized a syndrome induced in response to sleep deprivation especially composed of a progressive increase in food intake. Interestingly, Spiegel et al. (55) has shown that humans who are sleep restricted for 2 days (sleeping 4 h/night) were hungrier and developed a craving for food with a high carbohydrate content. Later, the hyperphagic behavior during sleep deprivation was attributed to an increase and decrease in the hypothalamic expression of neuropeptide Y (NPY) and proopiomelanocortin (POMC), respectively (20). Supporting such changes in these neuropeptides, earlier studies in different species have found a reduction in circulating levels of leptin in response to sleep loss (11,22,55,56). Although the d...

show abstract

Section: Discussionsupporting

confidence: 57%

Orexin activation precedes increased NPY expression, hyperphagia, and metabolic changes in response to sleep deprivation

Martins¹,

Marques²,

Tufik³

et al. 2010

American Journal of Physiology-Endocrinology and Metabolism

View full text Add to dashboard Cite

show abstract

“…This phase is generally considered as a direct consequence of the effects of mediators released from mast cells activated during the early reaction. Inflammatory and allergic diseases are mainly orchestrated by antigen-specific CD4+ T cells, eosinophils and mast cells (55). Prostanoids are one of the arachidonic metabolites, which are produced by a variety of inflammatory cells upon stimulation and are thought to be involved in the pathogenesis of diseases as well as the regulation of homeostasis.…”

mentioning

confidence: 99%

Mast Cells and Arachidonic Acid Cascade in Inflammation

et al. 2009

View full text Add to dashboard Cite

Prostaglandin D2 PGD2 is a major cyclooxygenase metabolite of arachidonic acid produced by mast cells and it is released following allergen challenge in diseases, such as allergic diseases. PGD2 may act as a neuromodulator and as an allergic and inflammatory mediator. In allergic diseases, activated mast cell synthesizes prostaglandin D2 (first cyclo-oxygenate mediator) which has bronchoconstrictive and vasodilating effects and attracts several leukocytes. It has been found that activated mast cells, challenged with physiological and non- physiological secretagogues, release elevated histamine and tryptase and chymase, leukotrienes B4, C4 and D4, 5-hydroxyeicosatetraenoic acid, PGD2, Platelet Activating Factor (PAF), heparin, and high-molecular-weight neutrophil chemotactic factor and cytokines/chemokines. PGD2 exerts its biological activity through the DP and CRTH2 receptors and their cDNA cloning which were characterized 15 years ago. In this report, we revisited the biological effects of arachidonic acid compounds released by activated mast cells in allergic and inflammatory states.

show abstract